Collagen meniscus implants are a medical device used to replace injured meniscus (cushion present inside the knee joint) during partial or total meniscectomy (surgical removal of meniscus). The meniscus acts as a shock absorber and stabilizes the knee joint. Damage or tear in the meniscus can occur due to sports injuries or normal wear & tear resulting in instability, swelling and pain in the knee joint. Collagen meniscus implants help restore the knee stability and functionality after meniscal tears. The implants are manufactured using type I collagen, the main structural protein present in the native meniscus. Collagen implants offer a scaffold for tissue regeneration and are absorbed gradually by the body as new meniscal tissue forms.
The Global Collagen Meniscus Implant Market is estimated to be valued at US$ 542.25 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Collagen Meniscus Implant Market are Thermo Fisher Scientific, Sigma-Aldrich Corporation, GE Healthcare, Integrated DNA Technologies, Inc., TriLink Biotechnologies€TM, Inc, BioAutomation Corporation, Twist Bioscience, Shanghai SynTheAll Pharmaceutical Co., CUSABIO Technology LLC, Synbio Technologies, GENEWIZ, Eurofins Scientific, Agilent Technologies, Kaneka Eurogentec S.A., and LGC, Biosearch Technologies.
The key opportunities in the market include development of implants with longer shelf life, use of regenerative techniques like stem cells for meniscus repair and global expansion into emerging economies of Asia Pacific and Latin America.
Leading players are focusing on global expansion plans by partnering with local distributors to tap the high growth potential markets in China, India and Brazil. For instance, in 2022 GE Healthcare partnered with diagnostic chain Dr. Lal PathLabs to distribute its cell culture media and reagents in India.
Market Drivers
Growing geriatric population susceptible to age-related meniscal tears is a key factor driving the market. According to the UN, over 16% of the global population will be aged over 65 years by 2050.
Advancements in collagen implant technology leading to development of implants with bioabsorbable fiber structure mimicking the anisotropic properties of native meniscus is supporting the usage of collagen implants procedures.
Market Restraints
High cost of collagen meniscus implant procedures restricts adoption in cost-sensitive regions. The average cost of collagen meniscus implant surgery in the US ranges between US$ 10,000–15,000.
Concerns regarding unpredictable implant resorption rate and long term efficacy & safety which is still under clinical evaluation is hindering widespread commercial adoption.
Segment Analysis
The Collagen Meniscus Implant Market Demand is dominated by the Allografts segment. Allografts involve transplanting tissue from one individual to another of the same species. Being non-synthetic implants and having good biocompatibility with the articular cartilage makes allografts preferred over synthetic options. With advancements in tissue preservation methods like cryopreservation and availability of fresh-frozen meniscal allografts, the allograft segment is growing steadily.
Global Analysis
The Europe region dominates the Collagen Meniscus Implant market currently in terms of revenue due to growing awareness, high diagnostic rates and the presence of leading manufacturers. Increase in public funding for research activities and new product launches are fuelling market growth in the region. Asia Pacific region is expected to witness highest growth during the forecast period owing to improving healthcare infrastructure, rising medical tourism and increasing investments from market players looking to tap opportunities in emerging economies. Population expansion and growing geriatric population susceptible to orthopedic issues also contribute to market growth in Asia Pacific.
For more insights, read-https://www.pressreleasebulletin.com/collagen-meniscus-implant-market-trends-size-and-share-analysis/
Comments
0 comment